J Saadh Mohamed, N A Jafar Nadhir, Altalbawy Farag M A, Sharma Pawan, Kumar Abhishek, Alamir Hassan Thoulfikar A, Ghazy Hameed, Noori Shakir Maha, Khudhur Mohammed Saad, Muzammil Khursheed, Chasib Gabal Baneen
Faculty of Pharmacy, Middle East University Amman 11831 Jordan.
Al-Zahraa Center for Medical and Pharmaceutical Research Sciences (ZCMRS), University of Al-Zahraa for Women Kerbala 65001 Iraq
RSC Adv. 2024 Aug 5;14(34):24473-24482. doi: 10.1039/d4ra03758h.
Currently, nanocomposites are synthesized and used in various fields. One of the applications of these nanostructures is in the medical field. Therefore, the synthesis of new composites with biological properties is important. In this study, under microwave conditions, a new nanocomposite containing molybdenum and [2,2'-bipyridine]-4,4'-dicarboxylic acid (Mo/BPDA) was synthesized. The synthesized Mo/BPDA composite was subjected to biological evaluations such as antibacterial and antifungal properties by clinical and laboratory standards institute guidelines, and anticancer properties by MTT method. Characterization and structure characteristics of the Mo/BPDA nanocomposite were evaluated using XRD (X-ray diffraction pattern), FT-IR (Fourier-transform infrared), EDAX (energy-dispersive X-ray), EA (elemental analysis), TGA/DTG (thermogravimetric analysis/differential thermogravimetry), SEM (scanning electron microscopy) and BET (Brunauer-Emmett-Teller) analysis. The results indicated relatively high thermal stability (300 °C), high specific surface area (35 cm g) and uniform morphology of the synthesized Mo/BPDA nanocomposite. In antibacterial and antifungal activity, minimum inhibitory concentration (between 2 and 256 μg mL), minimum bactericidal concentration (between 4 and 128 μg mL), and minimum fungicidal concentration (between 64 and 256 μg mL) were tested and reported. The results showed that the antibacterial and antifungal activity of Mo/BPDA nanocomposite is higher than that of antibiotic drugs such as ampicillin, cefazolin, ketoconazole, and nystatin. In the investigation of the anticancer activity that was tested against bone cancer cells and breast cancer cells for 24 and 48 hours, cell proliferation and viability (37.3648-82.0674 tan control) and IC (33-43 μg mL) were observed. As a final result, it can be stated that the synthesized Mo/BPDA nanocomposite after the additional biological evaluations, such as study, can be used as an efficient option in treating bone cancer cells and breast cancer cells and a strong antibiotic on a wide range of infectious diseases.
目前，纳米复合材料被合成并应用于各个领域。这些纳米结构的应用之一是在医学领域。因此，合成具有生物特性的新型复合材料很重要。在本研究中，在微波条件下，合成了一种含有钼和[2,2'-联吡啶]-4,4'-二羧酸的新型纳米复合材料（Mo/BPDA）。通过临床和实验室标准协会指南对合成的Mo/BPDA复合材料进行了抗菌和抗真菌等生物学评估，并通过MTT法进行了抗癌性能评估。使用XRD（X射线衍射图谱）、FT-IR（傅里叶变换红外光谱）、EDAX（能量色散X射线光谱）、EA（元素分析）、TGA/DTG（热重分析/微分热重分析）、SEM（扫描电子显微镜）和BET（布鲁诺尔-埃米特-特勒）分析对Mo/BPDA纳米复合材料的表征和结构特征进行了评估。结果表明，合成的Mo/BPDA纳米复合材料具有较高的热稳定性（300℃）、较高的比表面积（35 cm²/g）和均匀的形态。在抗菌和抗真菌活性方面，测试并报告了最低抑菌浓度（2至256μg/mL之间）、最低杀菌浓度（4至128μg/mL之间）和最低杀真菌浓度（64至256μg/mL之间）。结果表明，Mo/BPDA纳米复合材料的抗菌和抗真菌活性高于氨苄西林、头孢唑林、酮康唑和制霉菌素等抗生素药物。在针对骨肉瘤细胞和乳腺癌细胞进行24小时和48小时的抗癌活性研究中，观察到细胞增殖和活力（37.3648 - 82.0674，与对照组相比）以及IC50（33至43μg/mL）。最终结果表明，经过进一步的生物学评估后，合成的Mo/BPDA纳米复合材料可作为治疗骨肉瘤细胞和乳腺癌细胞的有效选择，以及对多种传染病具有强效抗菌作用的药物。
